{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:20:38Z","timestamp":1701858038599},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00066-023-02051-3","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T14:17:28Z","timestamp":1675779448000},"page":"333-336","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiovaskul\u00e4re Risikoevaluation in der Behandlung des Hodgkin-Lymphoms\u00a0\u2013 auf dem Weg zur individualisierten Planung?"],"prefix":"10.1007","volume":"199","author":[{"given":"Michael","family":"Oertel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"2051_CR1","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs\u00a0M, Goergen\u00a0H, Kobe\u00a0C et al (2019) Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J\u00a0Clin Oncol 37:2835\u20132845. https:\/\/doi.org\/10.1200\/JCO.19.00964","journal-title":"J Clin Oncol"},{"key":"2051_CR2","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9\u00a0MPE, Girinsky\u00a0T, Federico\u00a0M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J\u00a0Clin Oncol 35:1786\u20131794. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"},{"key":"2051_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford\u00a0J, Illidge\u00a0T, Counsell\u00a0N et al (2015) Results of a\u00a0trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"2051_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann\u00a0P, Pl\u00fctschow\u00a0A, Kobe\u00a0C et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a\u00a0multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223\u2013234. https:\/\/doi.org\/10.1016\/S1470-2045(20)30601-X","journal-title":"Lancet Oncol"},{"key":"2051_CR5","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.21.00408","volume":"39","author":"DJ Cutter","year":"2021","unstructured":"Cutter\u00a0DJ, Ramroth\u00a0J, Diez\u00a0P et al (2021) Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin Lymphoma. J\u00a0Clin Oncol 39:3591\u20133601. https:\/\/doi.org\/10.1200\/JCO.21.00408","journal-title":"J Clin Oncol"},{"key":"2051_CR6","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0024","author":"U Hoeller","year":"2021","unstructured":"Hoeller\u00a0U, Borgmann\u00a0K, Oertel\u00a0M et\u00a0al (2021) Late sequelae of radiotherapy\u2014the effect of technical and conceptual innovations in radiation oncology. Dtsch Aerztebl. https:\/\/doi.org\/10.3238\/arztebl.m2021.0024","journal-title":"Dtsch Aerztebl"},{"key":"2051_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01682-0","author":"NB Pepper","year":"2020","unstructured":"Pepper\u00a0NB, Oertel\u00a0M, Kittel\u00a0C et\u00a0al (2020) Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin\u2019s lymphoma. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-020-01682-0","journal-title":"Strahlenther Onkol"},{"key":"2051_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.HS9.0000890936.73031.da","volume":"6","author":"M Oertel","year":"2022","unstructured":"Oertel\u00a0M, Hering\u00a0D, Nacke\u00a0N et al (2022) P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy\u2014implications from the GHSG HD 17 trial. HemaSphere 6:42\u201342. https:\/\/doi.org\/10.1097\/01.HS9.0000890936.73031.da","journal-title":"HemaSphere"},{"issue":"3","key":"2051_CR9","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","volume":"8","author":"M Oertel","year":"2023","unstructured":"Oertel\u00a0M et al (2023) Radiation Therapy in the German Hodgkin Study Group HD\u00a016 and HD\u00a017 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era. Adv Radiat Oncol 8(3):101169. https:\/\/doi.org\/10.1016\/j.adro.2022.101169","journal-title":"Adv Radiat Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02051-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T18:40:05Z","timestamp":1676659205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02051-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2051"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02051-3","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"19 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der korrekte Interessenkonflikt lautet: Interessenkonflikt H.T.\u00a0Eich und M.\u00a0Oertel geben folgenden Interessenkonflikt an: F\u00f6rderung zur Radiotherapie des Hodgkin Lymphoms durch die Deutsche Krebshilfe (Projekt 70112331).","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.T.\u00a0Eich und M.\u00a0Oertel geben folgenden Interessenkonflikt an: F\u00f6rderung zur Radiotherapie des Hodgkin Lymphoms durch die Deutsche Krebshilfe (Projekt 70112331).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}